Canadian Association of Radiopharmaceutical Scientists


May 23, 2019
Radiopharmacist (Fedoruk Centre)

Job Profile: The Sylvia Fedoruk Canadian Centre for Nuclear Innovation Inc. (Fedoruk Centre) is inviting applications for a Radiopharmacist: (a) to ensure quality control and safety of novel radiopharmaceuticals, in compliance with regulations of Health Canada and the Canadian Nuclear Safety Commission; and (b) to provide collaborative scientific support for researchers who access the specialized facilities at the Saskatchewan Centre for Cyclotron Sciences (SCCS) to advance their programs of innovation in nuclear imaging or therapy towards clinical applications. The Fedoruk Centre was established in 2011 under the Canada Not-for-Profit Corporations Act, with an independent Board of Directors and a sole Member, the University of Saskatchewan (U Sask). The purpose of the Fedoruk Centre is to help place Canada among global leaders of nuclear research, development and training through investment in partnerships with academia and industry. The SCCS is owned by U Sask and operated by the Fedoruk Centre. Commencing operation in 2015, this $25 million facility features a high-current ACSI TR24 cyclotron; a cGMP-level radiopharmaceutical laboratory including hot cells, auto-synthesis units and a quality control system (HPLC, GC, TLC); and a small-animal SPECT-PET-CT scanner for preclinical research. An additional investment of $5M was secured from provincial and federal agencies in 2018 to establish an innovation complex of shielded work areas, radiochemistry equipment and a new high-throughput PET-CT instrument, for access by users to develop new nuclear imaging agents for disease-targeting diagnoses and treatments. Besides serving as a centre of scientific collaborations and partnerships among the province’s two universities, the Saskatchewan Health Authority and industry, the SCCS supplies fludeoxyglucose (FDG) for PET-CT scanning at the Royal University Hospital in Saskatoon, enabling more than 2500 patients each year to receive medical scans for diagnosis of cancer. The SCCS is licensed by the Canadian Nuclear Safety Commission (CNSC) as a Class II Nuclear Facility. Radiopharmaceuticals are manufactured in compliance with regulations of the CNSC and Health Canada. The salary range for this Radiopharmacist position is $87,000 - $145,750 per annum. Placement within the range is dependent upon education and experience. This is a continuing full-time position that is not within any collective bargaining unit.

Accelerate Internship Opportunities
PDF-Production of Gallium-68 on High Current Cyclotron Solid Target - ON-173
Preferred Disciplines: Medical Biophysics, Chemical Engineering (Post-Doc)
Company: ARTMS Products Inc. Project Length: 2 years (6 units) Desired start date: As soon as possible Location: This posting is looking for a PDF to work with Dr. Michael Kovacs (Western University) in partnership with ARTMS, based in British Columbia.

Project Description: This Postdoctoral fellow will design, implement and test a novel cyclotron target for the production of gallium-68. This project will be performed as a collaboration between Lawson Health Research, ARTMS Products Inc. and TRIUMF. Gallium-68 is an emerging and important isotope used for the diagnosis and treatment monitoring of prostate cancer. The postdoctoral candidate will have the opportunity to work independently or with colleagues in the use of various metal manufacturing techniques and chemistry methods to detail target performance and isotope yields and purity. Being a joint position between these organizations, the Postdoctoral candidate will work roughly 50% of the time in Vancouver doing target development and 50% in London performing tests at the Lawson cyclotron facility.

Research Objectives:​

  • Develop a novel target design including automated target dissolution, purification and radiopharmaceutical preparation and quality control.
  • Leverage past chemical engineering experience to study and establish target performance specifications during and after proton irradiation.
  • Represent the project at conference symposia and publish the study data in the peer reviewed literature

Methodology: To be determined

Expertise and Skills Needed: Ph.D. in Chemistry, Chemical Engineering or equivalent field of research. A knowledge of isotope-based research is preferred. In addition, candidates should have the ability to learn to safely prepare and handle radiopharmaceuticals. Skills will be developed in the areas of high-temperature sintering techniques, electroplating, electrodeposition, chromatography, radiation detectors, and other analytical devices. more>

09 Sep 2018
Radiopharmaceutical Chemistry Technician RA3
Reference # 74303
Temporary Full Time (Until Sept 2022) Vancouver, BC

Under limited supervision, the Radiopharmaceutical Chemistry Technician (RA3) prepares routine radiopharmaceuticals for the Centre of Excellence for Functional Cancer Imaging. The Technician is responsible for producing a daily supply of radiopharmaceuticals to meet the scheduled workload at the PET facility while ensuring that all procedures and protocols for radiopharmaceutical production are followed accurately. This requires the daily coordination of the production of the required quantity of radioisotopes from the cyclotron, production of radiopharmaceuticals using a manual methods or synthesis modules, completion of required quality controls and documentation of all results. The Technician troubleshoots and resolves technical equipment problems as necessary in order to maintain daily radiopharmaceutical output and clinical or research patient throughput. The Technician assists in the development of standard operating procedures that will help establish GMP-compliance for the facility as a producer/distributor of PET radiopharmaceuticals. This responsibility includes providing orientation to new radiochemistry staff and contributing to the preparation of scientific papers or grant applications as required. Works collaboratively on research activities with external groups as required. This position is grant-funded for 4 years with possibility of extension to 5 years, for the purpose of production of Lu-177 and Ac-225 labelled radiopharmaceuticals in development of new radiotherapies. Majority of time will be spent at TRIUMF - Canada’s particle accelerator centre, due to collaborative nature of the project.

Last updated:22 October, 2018
Home | About Us | Radiopharmacy News | Members Only | | Meetings | Radiopharmacy Job Postings | Contact Us |
Terms of Use
Copyright © 2018 Canadian Association of Radiopharmaceutical Scientists | Webmaster Mariusz Bereznicki